Vita-Salute San Raffaele University, Milan, Italy.
SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
J Acquir Immune Defic Syndr. 2021 Feb 1;86(2):219-223. doi: 10.1097/QAI.0000000000002542.
Syphilis has been increasing in the past years, especially among men who have sex with men (MSM). The aim of the study was to assess syphilis prevalence and incidence and changes in CD4 count and viremia in the RV254 cohort of persons living with HIV who initiated antiretroviral therapy during acute HIV infection (AHI) in Bangkok, Thailand.
From 2009 to 2018, all cohort participants with AHI were tested for syphilis using a qualitative treponemal chemiluminescent microparticle immunoassay and rapid plasma reagin on enrollment, every 24-48 weeks thereafter and when clinically indicated. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for factors associated with incident syphilis.
Among 579 participants, the median age was 26 (interquartile range: 22-31) years and 564 (97.4%) were men. Syphilis prevalence at enrollment was 14.3% and incidence was 10.2 cases per 100 person-years. Participants with syphilis were more likely to be MSM (HR 3.68, 95% CI: 1.16 to 11.62), use methamphetamine (HR 2.31, 95% CI: 1.51 to 3.54), and have hepatitis C (HR 2.63, 95% CI: 1.59 to 4.34). HIV RNA >50 copies/mL occurred in 6 (3.9%) participants at incident syphilis diagnosis and in 6 (3.9%) after syphilis treatment. Median CD4 count (cells/mm3) declined from 663 before syphilis to 624 at syphilis diagnosis (P = 0.07), rising again to 660 after syphilis treatment.
Syphilis was common in the RV254 cohort, inducing a marginal but significant impact on HIV RNA and a temporary decline in CD4. Syphilis screening and behavioral risk reduction counseling should be implemented for MSM with AHI in Thailand.
梅毒在过去几年呈上升趋势,尤其是在男男性行为者(MSM)中。本研究旨在评估泰国曼谷 RV254 队列中在急性 HIV 感染(AHI)期间开始接受抗逆转录病毒治疗的 HIV 感染者的梅毒患病率和发病率以及 CD4 计数和病毒载量的变化。
2009 年至 2018 年,所有 AHI 队列参与者在入组时使用定性梅毒螺旋体化学发光微粒子免疫测定和快速血浆反应素进行梅毒检测,此后每 24-48 周以及临床需要时进行检测。使用 Cox 比例风险模型估计与梅毒发病相关的因素的风险比(HR)和 95%置信区间(CI)。
在 579 名参与者中,中位年龄为 26(四分位距:22-31)岁,564 名(97.4%)为男性。入组时梅毒患病率为 14.3%,发病率为 10.2 例/100 人年。患有梅毒的参与者更有可能是 MSM(HR 3.68,95%CI:1.16-11.62),使用冰毒(HR 2.31,95%CI:1.51-3.54)和丙型肝炎(HR 2.63,95%CI:1.59-4.34)。在发生梅毒的诊断时,有 6 名(3.9%)参与者的 HIV RNA>50 拷贝/mL,在梅毒治疗后有 6 名(3.9%)参与者的 HIV RNA>50 拷贝/mL。梅毒诊断前 CD4 计数(细胞/mm3)中位数为 663,梅毒诊断时为 624(P=0.07),梅毒治疗后再次升高至 660。
梅毒在 RV254 队列中很常见,对 HIV RNA 产生了轻微但显著的影响,并导致 CD4 暂时下降。在泰国,应对 AHI 的 MSM 进行梅毒筛查和行为风险降低咨询。